The Osteosarcoma Institute to fund clinical trial in recurrent osteosarcoma at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
February 27, 2020
Osteosarcoma Institute (OSI) announced today that it has awarded a grant to
Dana-Farber/Boston Children’s Cancer and Blood Disorders Center for a Phase II single
arm study of olaparib (an FDA-approved PARP inhibitor) and ceralacertib/AZD6738
(an investigational ATR kinase inhibitor) in patients with recurrent osteosarcoma.
Both study drugs are orally-administered and are products of AstraZeneca which is supporting the
trial by providing these agents. The trial also features important correlative
biology studies to help understand what genomic characteristics and biomarkers
can best predict patients who may respond to this regimen.
The trial will be led by Katherine
A. Janeway, MD, MMSc, Senior Physician at Dana-Farber/Boston Children's and
Director of Clinical Genomics at Dana-Farber Cancer Institute.
It is expected to open at both Dana-Farber/Boston Children’s and University of
California, San Francisco this summer and at least one other institution in late
Janeway commented, “We are excited to be partnering with OSI and AstraZeneca to launch a
trial of this drug combination in osteosarcoma. In this phase 2 trial of
olaparin and ceralacertib, OSI is supporting a unique linkage between Dr.
Sweet-Cordero’s basic science laboratory and our clinical trials group ensuring
that we use every opportunity to advance our understanding of osteosarcoma.”
Osteosarcoma is the most common bone tumor among children, adolescents, and young adults
and, unlike many other pediatric cancers, there has been no significant
improvement in outcomes in the past 30 years. Effective new treatments are desperately needed for patients whose disease recurs after initial therapy.
About the Osteosarcoma Institute
The Osteosarcoma Institute (www.osinst.org, @OSInstitute),
is a 501(c)(3) public charity formed in 2017 to dramatically improve treatments
for osteosarcoma patients, particularly those with relapsed and metastatic
disease. It funds pre-clinical research to gain understanding of the biology of osteosarcoma and clinical trials to
evaluate the safety and effectiveness of potential new treatments.